Management of heart failure with reduced ejection fraction in 2021: an update for GPs

INTRODUCTION
In February 2021, the National Institute for Health and Care Excellence (NICE) approved the use of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), for patients with or without diabetes and with a left ventricular ejection fraction (LVEF) of <40%.1 This article provides some practical guidance for GPs on implementing the recommendation.

WHAT DRUGS ARE CURRENTLY IN USE FOR HEART FAILURE WITH REDUCED EJECTION FRACTION TO IMPROVE PROGNOSIS?
Until recently, three groups of drugs were recommended by NICE as standard therapy to improve symptoms and prognosis in heart failure with reduced ejection fraction (HFrEF). The aspiration is for patients to receive them at the maximal tolerated doses (Table 1). The groups are: angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers (BB); and – for patients remaining symptomatic – mineralocorticoid receptor antagonists (MRA).

In patients with persistent or worsening symptoms whose LVEF is <35%, any ACEI/ARB should be replaced with sacubitril-valsartan (Entresto®), the current sole licensed member of ARNI, as both symptoms and prognosis are improved.2

WHY IS DAPAGLIFLOZIN REQUIRED IN HEART FAILURE WITH REDUCED EJECTION FRACTION?
Chronic heart failure still carries a poor prognosis, worse than some cancers, with a mortality of 42% at 5 years after the diagnosis in the UK.3 In part this reflects incomplete optimisation of existing therapies. GPs have a major role to play in spotting the need for medicines optimisation (Table 1), considering non-pharmacological interventions, and liaising with the community heart failure nurse and cardiac rehabilitation teams.

In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, addition of dapagliflozin reduced the composite cardiovascular endpoint (hospitalisation for heart failure, urgent outpatient diuretic, therapy, or cardiovascular death) by 26% with a Number Needed to Treat (NNT) of 21, effects being seen within days, and statistically significant within 4 weeks.4 Benefits accrued irrespective of baseline drug or device therapies.

SGLT2is reduce renal tubular glucose and sodium reabsorption, resulting in a net decrease in blood glucose, without insulin stimulation.5 To what extent the observed benefits of SGLT2is in HFrEF are due to a glycosuria-driven diuresis,6 natriuresis, renoprotection, or an as yet unidentified mechanisms is unclear.4

As there is evidence of similar benefits in HFrEF from empagliflozin,7 in the authors’ view and pending national guidance, patients already prescribed this medication for their diabetes need not be changed to dapagliflozin.

HOW DOES STEPWISE PHARMACOTHERAPY WORK IN PRACTICE AND WHERE DOES DAPAGLIFLOZIN FIT IN?
All patients with newly diagnosed HFrEF should promptly receive adequate diuretics to achieve euvolemia. An ACEI/ARB is started as soon as possible. Drugs with prognostic benefit should be up-titrated to the maximum tolerated doses in 1–2 weekly intervals, taking careful account of heart rate (with beta-blockers), blood pressure, and renal function (Table 1). If symptoms persist, especially if LVEF is <35%, an MRA should be added, or substituted for a loop diuretic, to further reduce hospitalisations and improve prognosis.

M Shanmuganathan, BSc, MRCP, post CCT cardiology research fellow, Division of Cardiovascular Medicine, University of Oxford, Oxford, UK; Harefield Hospital, Royal Brompton and Harefield Hospitals, Harefield, UK. R Goswami, MD, FACC, transplant cardiologist, Mayo Clinic, Jacksonville, Florida, US. O Dar, MD, MRCP, consultant cardiologist, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, UK. C A’Court, MA, MRCP, MRCGP, GP with extended role in cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; clinical researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Address for correspondence
Christine A’Court, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Emails: christine.acourt@phc.ox.ac.uk
Submitted: 15 March 2021; Editor’s response: 13 April 2021; final acceptance: 9 May 2021.
DOI: https://doi.org/10.3399/bjgp21X716429

DAPAGLIFLOZIN FIT IN?
All patients with newly diagnosed HFrEF should promptly receive adequate diuretics to achieve euvolemia. An ACEI/ARB is started as soon as possible. Drugs with prognostic benefit should be up-titrated to the maximum tolerated doses in 1–2 weekly intervals, taking careful account of heart rate (with beta-blockers), blood pressure, and renal function (Table 1). If symptoms persist, especially if LVEF is <35%, an MRA should be added, or substituted for a loop diuretic, to further reduce hospitalisations and improve prognosis.
CO-TRANSPORTER-2 INHIBITOR USAGE IN HEART FAILURE?

While most GPs have experience of initiating beta-blockers, ACEI, or ARB, they may be less familiar with SGLT2i, even in the context of diabetes mellitus. Ironically, prescribing of dapagliflozin for HFREF is most straightforward in patients without diabetes. An SGLT2i does not lower blood glucose if a patient is normoglycaemic. However, if a patient with type 2 diabetes mellitus is on insulin or insulin secretagogues [sulfonylureas or meglitinides] their doses may need to be reduced by 20% and 25–50% respectively to reduce the risk of hypoglycaemia. Such dose reductions should be personalised and a diabetologist’s input is advisable.

Many HFREF patients have renal impairment. Although previous advice was to avoid initiating SGLT2is in patients with eGFR <60 ml/min/m² and to discontinue if it fell to <45 ml/min/m², this reflected the diminishing glucose-lowering impact as renal tubular function declines. When prescribing dapagliflozin for HFREF the marketing authorisation and NICE simply cautioned that there is limited experience with dapagliflozin in HFREF when eGFR is <30 ml/min/m². It is now widely accepted that SGLT2is are not only safe when eGFR is >20 ml/min/m² but SGLT2is also reduce the rate of decline in renal function in HFREF. An imminent licence for renoprotection is anticipated.6,7 No dose adjustment is required for dapagliflozin in renal impairment (unlike empagliflozin).

Although there was a widespread expectation that initiation of SGLT2is in patients on diuretics might lead to over-diuresis/dehydration,6 in chronic heart failure (as opposed to acute decompensated patients) experience suggests the majority of patients do not routinely need diuretic dose reduction. After a transient dip of experience suggests avoidance in patients with a baseline systolic blood pressure of <95–100 mmHg.

In some patients, hypotension, bradycardia, or hyperkalaemia make it impossible to achieve the target doses for the ‘four pillars’ of drug therapy (Table 1). In such cases, most specialists advocate use of all indicated drugs at lower, tolerated doses. Reducing diuretic dose [MRAs] or frequency [loop diuretics] to the minimum possible when the patient is euvoalaemic may help achieve target doses for the other drugs.

WHAT ARE THE POTENTIAL CHALLENGES WITH SODIUM-GLUCOSE CO-TRANSPORTER–2 INHIBITOR USAGE IN HEART FAILURE?

Table 1. First- and second-line pharmacotherapy groups (‘the four pillars’) known to reduce mortality in HFREF and approved by NICEa

<table>
<thead>
<tr>
<th>Groups of pharmacotherapy for HFREF</th>
<th>Starting dose (examples)</th>
<th>Number of titrations needed</th>
<th>Target dose (examples)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Beta-blocker</td>
<td>Bisoprolol 2.5 mg o.d.</td>
<td>3–4</td>
<td>Bisoprolol 10 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Carvedilol 3.125 mg b.d.</td>
<td></td>
<td>Carvedilol 25–50 mg b.d.</td>
</tr>
<tr>
<td>2. ACEI or ARB or ARNIb</td>
<td>Ramipril 2.5 mg o.d.</td>
<td>3–4</td>
<td>Ramipril 10 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Perindopril erbumine 2 mg o.d.</td>
<td></td>
<td>Perindopril erbumine 4–8 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Lisinopril 2.5 mg o.d.</td>
<td></td>
<td>Lisinopril 35 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Losartan 12.5 mg o.d.</td>
<td>4</td>
<td>Losartan 150 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Valsartan 40 mg b.d.</td>
<td></td>
<td>Valsartan 160 mg b.d.</td>
</tr>
<tr>
<td></td>
<td>Candesartan 4 mg o.d.</td>
<td></td>
<td>Candesartan 32 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Sacubitril–valsartan 48/52 mg b.d., or 24/26 mg b.d. if BP low</td>
<td>1–2</td>
<td>97/103 mg b.d.</td>
</tr>
<tr>
<td>3. MRA</td>
<td>Spironolactone 25 mg o.d.</td>
<td>2–3</td>
<td>Spironolactone 50 mg o.d.</td>
</tr>
<tr>
<td></td>
<td>Eplerenone 25 mg o.d.</td>
<td></td>
<td>Eplerenone 50 mg o.d.</td>
</tr>
<tr>
<td>4. SGLT2i</td>
<td>Dapagliflozin 10 mg o.d.</td>
<td>0</td>
<td>Dapagliflozin 10 mg o.d.</td>
</tr>
</tbody>
</table>

aTypical starting and final doses of the most commonly used drugs are listed. Titrations are typically done every 1–2 weeks. bARNIs’ prognostic benefits are superior to ACEI or ARB but NICE reserves it for patients with LVEF <35% and symptoms. ACEI = angiotensin-converting enzyme inhibitor. ARB = angiotensin receptor blocker. ARNI = angiotensin-neprilysin inhibitor; b.d. = twice a day. BP = blood pressure. HFREF = heart failure with reduced ejection fraction. LVEF = left ventricular ejection fraction. MRA = mineralocorticoid receptor antagonist. NICE = National Institute for Health and Care Excellence. o.d. = once a day.

If a patient remains symptomatic on combined ACEI/ARB, beta-blockers, and MRA, and has a qualifying ejection fraction (<40% for dapagliflozin and ≤35% for ARNI, as per NICE) then these two drug classes offer additive and complimentary benefits.1 Although NICE recommends that dapagliflozin 10 mg (once a day) is added in symptomatic patients as an add-on to optimised standard care, the relative ease of prescribing dapagliflozin with its single dose and lesser monitoring requirements may promote its introduction before ARNI.

NICE advises that, where the indication is HFREF, initiation of dapagliflozin should be on the advice of a heart failure specialist in primary, secondary, or community care.1 Specialist input is less sure of contraindications are recognised, primarily type 1 diabetes mellitus, or previous history of diabetic ketoacidosis, and that due consideration is given to renal function, dose adjustment of co-prescribed oral hypoglycaemics, and risk factors for diabetic ketoacidosis.

Whether before or after dapagliflozin, specialist input such as from the community heart failure team is also required for replacement of the ACEI/ARB with ARNI and subsequent up-titration because ARNI are more inclined to cause hypotension, hyperkalaemia, and to potentiate diuretics. Notably, conversion from ACEI/ARB to ARNI requires a 48-hour wash-out period.

Experience suggests avoidance in patients with a baseline systolic blood pressure of <95–100 mmHg.
First line:
- ACEI/ARB
- beta-blocker
Diauretic if required
Report dry weight.
Advise self-weighing to assist early recognition of decompensation
Consider fluid (1.5–2 L) & salt (6 g) restriction, especially if decompensated or hyponatraemic
Check iron and replace by IV route

Community heart failure nurse input is key
Cardiac rehabilitation improves exercise capacity and quality of life

Device therapy:
Implantable cardiac defibrillator (ICD) if good life expectancy as reduces risk of sudden arrhythmic death
Combine with cardiac resynchronisation therapy (CRT) pacing if left bundle branch block and qualifying QRS duration to augment cardiac output and improve quality of life

WHAT ARE OTHER ESSENTIAL COMPONENTS OF GOOD CARE FOR PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION?

Adding dapagliflozin to pharmacotherapy in HFrEF is only one element of a package of good care. GPs should be aware of the benefits of all four pillars of pharmacotherapy, implantable cardiac devices and cardiac rehabilitation, working closely with community heart failure nurses, and considering palliative care when appropriate.

Provenance
Freely submitted; externally peer reviewed.

Competing interests
The authors have declared no competing interests.

Discuss this article
Contribute and read comments about this article: bjgp.org/letters

REFERENCES